Clinical trials: Lobular Breast Carcinoma
Ductal Carcinoma in Situ
A Pilot Pre-operative Window Trial of Black Cohosh in Women With Ductal Carcinoma in Situ
The investigators hypothesize that black cohosh, as a potentially therapeutic agent, will reduce the overall size and aggressiveness of ductal carcinoma in situ (DCIS) when given in a pre-operative setting.
- Trial name
- NCT01628536
- Testing
- Black cohosh
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Yale University
Ductal Carcinoma
Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer
Primary: To determine the pathological remission following the chemotherapy combination docetaxel and doxorubicin in large breast cancer Secondary: Clinical response rate To investigate the safety of docetaxel doxorubicin…
- Trial name
- NCT00461344
- Testing
- Docetaxel, Doxorubicin
- Volunteers
- 20 people
- Sponsor
- Sanofi
BRCA Mutation, PALB2 Gene Mutation
Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion
Circulating levels of Sex Hormone Binding Globulin (SHBG) are significantly associated with a decreased risk of breast cancer. The main aim of this clinical trial is to verify whether Low Dose Tamoxifen (LDT) increases…
- Conditions
- BRCA Mutation, PALB2 Gene Mutation, Ductal Carcinoma in Situ, Lobular Carcinoma in Situ
- Trial name
- TOLERANT (NCT06033092)
- Testing
- Tamoxifen 10 mg Tablet, Intermittent caloric restriction, Step counter Device
- Where
- 4 sites in Italy
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- European Institute of Oncology
Breast Atypical Hyperplasia, Breast Lobular Carcinoma in Situ
Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk
The investigators plan to prospectively study breast tissue changes after a short course of Tamoxifen (Tam).
- Conditions
- Breast Atypical Hyperplasia, Breast Lobular Carcinoma in Situ, Breast Atypical Lobular Hyperplasia, Breast Carcinoma
- Trial name
- NCT04570956
- Testing
- Tamoxifen, Topical 4-OHT( 4-hydroxytamoxifen)gel 4 mg/each breast/day, Questionnaire Administration
- Where
- 3 sites in United States
- Volunteers
- 65 people
- Sponsor
- Mayo Clinic
Breast Cancer, Invasive Breast Carcinoma
Effect of High Dose Vitamin D on Cancer Biomarkers and Breast Cancer Tumors
High-doses of Vitamin D (VD) may be used as targeted therapy against breast cancer. The investigators will assess the effect of high dose VD on the following biomarkers in the breast cancer cells: VDR, estrogen receptor (ER)…
- Conditions
- Breast Cancer, Invasive Breast Carcinoma, Ductal Carcinoma In-situ
- Trial name
- NCT02856503
- Testing
- Vitamin D3
- Sponsor
- Eli Avisar, MD
Breast Cancer, Ductal Breast Carcinoma in Situ
Bilingual Breast Cancer Educational Intervention for Hispanic Women With Stage I, Stage II, or Stage III Breast Cancer and Their Families or Caregivers
RATIONALE: Studying quality-of-life in patients having cancer treatment may identify the intermediate- and long-term effects of treatment on patients with cancer PURPOSE: This randomized clinical trial is studying how well an…
- Conditions
- Breast Cancer, Ductal Breast Carcinoma in Situ, Stage I Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT01043003
- Testing
- educational intervention, quality-of-life assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Non-small Cell Lung Cancer, Colorectal Cancer
A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China
This is a Phase 1, open-label dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) and assess the DLT of JAB-3312.
- Conditions
- Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04121286
- Testing
- JAB-3312
- Where
- 5 sites in China
- Volunteers
- 17 people
- Sponsor
- Allist Pharmaceuticals, Inc.
Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia
Impact of Dietary Inflammatory Potential on Breast Cancer Risk
This study evaluates the association of dietary inflammatory potential with breast cancer risk. Information collected in this study may help doctors to identify modifiable risk factors, screen high risk patients early, improve…
- Conditions
- Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Carcinoma, Breast Lobular Carcinoma In Situ
- Trial name
- NCT05178498
- Testing
- Follow-Up, Physical Examination, Questionnaire Administration
- Where
- United States
- Volunteers
- 960 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Breast Cancer
MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ
RATIONALE: Diagnostic procedures, such as MRI, may help find ductal carcinoma in situ and find out how far the disease has spread.
- Trial name
- NCT00874458
- Testing
- magnetic resonance imaging, radiomammography, ultrasound imaging
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Centre Antoine Lacassagne
Ovarian Neoplasms, Breast Neoplasms
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP).
- Conditions
- Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms
- Trial name
- FiREBOLT (NCT07213791)
- Testing
- LY4337713
- Where
- 30 sites in United States, China and 3 more
- Volunteers
- 340 people
- Sponsor
- Eli Lilly and Company
Mammary or Extramammary Paget's Disease
A Study on the Efficacy of Disitamab Vedotin in Advanced HER2-positive Paget's Disease.
This study is a single-center, phase II clinical trial. Patients with HER2-positive advanced breast and extramammary Paget's disease who met the eligibility criteria were enrolled after signing an informed consent form.
- Trial name
- NCT06561555
- Testing
- RC48
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Fudan University
Ductal Breast Carcinoma In Situ, Stage IA Breast Cancer
Extent of Breast Cancer and the Role of Pre-Operative Sonography and MRI
This clinical trial studies mammography and targeted ultrasound with or without whole-breast ultrasound or contrast-enhanced magnetic resonance imaging (MRI) in finding out the extent of disease before surgery in patients with…
- Conditions
- Ductal Breast Carcinoma In Situ, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT02587663
- Testing
- Contrast-enhanced Magnetic Resonance Imaging, Mammography, Therapeutic Conventional Surgery
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- University of Southern California
Lobular Breast Carcinoma, Gastric Cancer
Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours
The purpose of this study was to find out how effective the combination of crizotinib and fulvestrant was in shrinking lobular breast cancer tumours.
- Conditions
- Lobular Breast Carcinoma, Gastric Cancer, Triple Negative Breast Cancer, CDH1 Gene Mutation
- Trial name
- ROLo (NCT03620643)
- Testing
- Crizotinib Oral Capsule [Xalkori], Fulvestrant 50 MG/ML Prefilled Syringe [Faslodex or generic]
- Where
- 5 sites in United Kingdom
- Volunteers
- 33 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Breast Cancer
RAPID: Randomized Trial of Accelerated Partial Breast Irradiation
To determine if Accelerated Partial Breast Irradiation, using 3D CRT, is as effective as Whole Breast Irradiation following breast conserving surgery in women with an new histological diagnosis of ductal carcinoma in situ only or…
- Trial name
- NCT00282035
- Testing
- APBI utilizing 3D-CRT radiation, Whole breast irradiation
- Where
- 33 sites in Australia, Canada and 1 more
- Volunteers
- 2,135 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Ductal Carcinoma In Situ, Atypical Lobular Hyperplasia
Ruxolitinib for Premalignant Breast Disease
This study is evaluating how ruxolitinib affects premalignant breast cells. One half of the study participants will receive ruxolitinib for approximately 15 days, and the other half will receive a placebo (sugar pill) for…
- Conditions
- Ductal Carcinoma In Situ, Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, Lobular Carcinoma In Situ
- Trial name
- TBCRC042 (NCT02928978)
- Testing
- Ruxolitinib
- Where
- 8 sites in United States
- Volunteers
- 84 people
- Sponsor
- Julie Nangia
DCIS, Ductal Carcinoma in Situ
Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS
This study looks at the risks and benefits of active monitoring (AM) compared to surgery in the setting of a pragmatic prospective randomized trial for low risk DCIS.
- Trial name
- COMET (NCT02926911)
- Testing
- Surgery, Active Monitoring
- Where
- 141 sites in United States
- Volunteers
- 997 people
- Sponsor
- Alliance Foundation Trials, LLC.
Breast Cancer, DCIS
Genotype and Phenotype Guided Supplementation of TAMoxifen Standard Therapy With ENDOXifen in Breast Cancer Patients
In hormone-receptor positive breast cancer or DCIS (ductal carcinoma in situ) tamoxifen remains an important treatment option for patients before menopause and those patients after menopause who cannot be treated with…
- Trial name
- TAMENDOX (NCT03931928)
- Testing
- (Z)-Endoxifen supplementation according to genotype, (Z)-Endoxifen supplementation according to plasma levels
- Where
- 40 sites in Germany
- Volunteers
- 356 people
- Sponsor
- Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)
Breast Cancer, Early-stage Breast Cancer
Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)
This study evaluates the rates of radiation-specific toxicity, quality of life, and oncologic outcomes for early-stage breast cancer and ductal carcinoma in situ treated with 5-fraction whole breast irradiation (WBI) with a…
- Conditions
- Breast Cancer, Early-stage Breast Cancer, Ductal Carcinoma in Situ, DCIS
- Trial name
- H-ASSIST (NCT06902311)
- Testing
- Breast Radiotherapy
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Non-small Cell Lung Cancer, Colorectal Cancer
A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors
This is a Phase 1, first-in-human, open-label dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) and assess the DLT of JAB-3312.
- Conditions
- Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04045496
- Testing
- JAB-3312
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants…
- Conditions
- Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
- Trial name
- LIBRETTO-001 (NCT03157128)
- Testing
- LOXO-292
- Where
- 85 sites in United States, Australia and 14 more
- Volunteers
- 857 people
- Sponsor
- Eli Lilly and Company